



HYUNDAI Pharm. Co., Ltd.

www.hyundaipharm.co.kr/english

HYUNDAI Pharm. was founded in 1965 as a pharmaceutical company with the corporate philosophy of "Contributing to the improvement of the health of mankind" based on the philosophy of the CEO who aims at the esteem of human respect and transparent corporate spirit. As a global R&D company, we aim to fulfill our responsibilities for improving public health by focusing on developing new drugs and incrementally modified drugs through continuous investment.

Main Products

Product name	Active ingredients	Indications
Minoxyl - 3%, 5% Solution - 3%, 5% Gel	Minoxidil	Androgenetic alopecia
Minoxyl complex Solution 5%	Minoxidil, Vitamin V6 / E, L-menthol	Androgenetic alopecia
Tenormin Tab.	Atenolol	Hypertension, Angina Pectoris
Uremin Tab.	Desmopressin acetate	Nocturnal enuresis
Mirtapin Tab.	Mirtazapine	Major depressive disorder
Mirap Tab. / ER Tab.	Pramipexole HCl	Parkinson's disease
Hipezil Tab.	Donepezil HCl	Alzheimer's disease
Dimantin Tab.	Memantine HCl	Alzheimer's disease
Tamirin SR Tab.	Galantamine HCl	Alzheimer's disease
Pemirosal Tab. / Dry Syrup	Pemirolast potassium	Bronchial Asthma, Allergic Rhinitis
Surfolase Cap. / CR Tab.	Acebrophylline	Acute & chronic Bronchitis
Levotuss Tab. / Syrup	Levodropropizine	Acute & chronic Bronchitis
Clinium Vaginal Tab.	Dequalinium Chloride	Bacterial & Candida Vaginitis





CEO
Sang-Joon, Lee

Location
Hyundai Pharm Bldg, Bongeunsa Street 135, Gangnam-Gu, Seoul

Specialty
1. NCE - Diabetes
2. IMD – Fixed dose combination of Alzheimer's disease
3. IMD – Fixed dose combination of Respiratory disease

Tel / Fax / E-mail
T. 82-2-1666-9979
F. 82-2-2693-7628
E. jhhwang@hdpharm.co.kr

R&D Pipeline

	CODE	PROJECT	INDICATION	Discovery	Pre-clinical	Phase I	Phase II	Phase III	NDA
NCE	HDNO-1605 [HOB-047]	HD-6277 Novel antidiabetics	Type-2 Diabetes						
	BPDO-1603 [BPS-034]	New fixed-dose combination	Senile disease						
	HDDO-1728	New dosage form	Senile disease						
IMD	HDDO-1756	New fixed-dose combination	Endocrine disease						
	HDDO-1801	New fixed-dose combination	Respiratory disease	